Cagrilintide 10mg

Cagrilintide is a long-acting amylin analogue studied in obesity and metabolic research. It has been investigated for its effects on appetite signaling, body-weight reduction, and energy-balance pathways, and it is also being studied in combination with semaglutide as CagriSema in late-stage clinical development.

What Cagrilintide has been studied for

• appetite and satiety signaling
• obesity and body-weight reduction
• metabolic regulation
• amylin-receptor and calcitonin-receptor pathway research
• combination therapy with semaglutide in CagriSema

How it works, in simple terms
Cagrilintide is designed to mimic amylin, a hormone released with insulin that helps regulate fullness and food intake. It acts at amylin-related receptors and calcitonin receptors, which is why it is usually described as an amylin analogue or dual amylin/calcitonin receptor agonist.

Relevant study
“A Long-Acting Amylin Analog for the Treatment of Obesity.”

Helpful chemistry / mechanism source
“Development of Cagrilintide, a Long-Acting Amylin Analogue.”